We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Moves -1.07%: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $46.06 in the latest trading session, marking a -1.07% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.64%. Meanwhile, the Dow lost 1.08%, and the Nasdaq, a tech-heavy index, lost 1.82%.
Prior to today's trading, shares of the company had lost 7.8% over the past month. This has lagged the Medical sector's loss of 3.72% and the S&P 500's gain of 0.89% in that time.
Wall Street will be looking for positivity from CRISPR Therapeutics AG as it approaches its next earnings report date. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$1.83 per share. This would mark year-over-year growth of 18.3%. Our most recent consensus estimate is calling for quarterly revenue of $20.52 million, up 22704.44% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$4.97 per share and revenue of $271.03 million. These results would represent year-over-year changes of +40.55% and +22523.56%, respectively.
Investors should also note any recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Moves -1.07%: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $46.06 in the latest trading session, marking a -1.07% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.64%. Meanwhile, the Dow lost 1.08%, and the Nasdaq, a tech-heavy index, lost 1.82%.
Prior to today's trading, shares of the company had lost 7.8% over the past month. This has lagged the Medical sector's loss of 3.72% and the S&P 500's gain of 0.89% in that time.
Wall Street will be looking for positivity from CRISPR Therapeutics AG as it approaches its next earnings report date. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$1.83 per share. This would mark year-over-year growth of 18.3%. Our most recent consensus estimate is calling for quarterly revenue of $20.52 million, up 22704.44% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$4.97 per share and revenue of $271.03 million. These results would represent year-over-year changes of +40.55% and +22523.56%, respectively.
Investors should also note any recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.